Elizabeth Kornaga is a translational scientist, advisor, biostatistician, and quality and biosafety officer at the Tom Baker Cancer Centre Translational Labs in Calgary, Alberta. She is a Transformative Pathology Associate of OICR.
- Translational Scientist, Tom Baker Cancer Centre
- Clinical research
- Molecular Pathology
- Diagnostic development
- Ho CK, Kornaga EN, Klimowicz AC, …, Doll CM. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol. 2017; 145(1):176-184.
- Enwere EK, Kornaga EN, Dean M, …, Doll CM. Expression of PDL1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017; 30(4): 577-586.
- Arjumand W, Merry CD, Wang C, …, Kornaga E, …, Lees-Miller SP. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Oncotarget. 2016;7(50):82424-82439.
- Kornaga EN, Klimowicz AC, Guggisberg N, …, Magliocco AM. Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort. Mod Pathol. 2016;29(12):1492-1500.
- Kornaga EN, Klimowicz AC, Guggisberg N, …, Magliocco AM. A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Mod Pathol. 2016;29(8):799-809.
See Dr. Kornaga’s recent publications on PubMed.
- Alberta Graduate Student Scholarship, 2005
- MSc, University of Calgary
- BSc, McGill University
Opportunities to collaborate
To collaborate with Elizabeth Kornaga, please contact her directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.